Sub-Total: $0.00
VIP: Researching the Master Regulator of Immune Tolerance and Neuroprotection
In the world of biochemistry, some molecules act as quiet background players, while others demand a "Very Important" designation. VIP (Vasoactive Intestinal Peptide) falls firmly into the latter category. While its name might sound like an exclusive guest list at a high-end gala, this 28-amino-acid peptide is actually one of the most versatile master regulators in the mammalian system. Whether it’s telling the immune system to "cool it" or protecting neurons from a chemical firestorm, VIP is a focal point for researchers investigating the intersection of the nervous and immune systems.
Molecular Specifications
- Chemical Name: Vasoactive Intestinal Peptide (VIP)
- Molecular Formula: C₁₄₇H₂₃₈N₄₄O₄₂S
- Molecular Weight: 3326.8 g/mol
- Amino Acid Sequence: H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH₂
- CAS Number: 40077-57-4
- Structure: Linear polypeptide with a C-terminal amide.
Defining VIP: A Neuropeptide and Hormone
Vasoactive Intestinal Peptide (VIP) was originally isolated from the porcine intestine in the 1970s. While initially recognized for its potent vasodilatory (widening of blood vessels) effects in the gut, subsequent research has reclassified it as a vital neuropeptide and cytokine-like hormone. It belongs to the glucagon/secretin superfamily, sharing structural similarities with compounds like PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide).
In the human body, VIP is produced by neurons, endocrine cells, and immune cells. Its wide distribution, spanning the central nervous system (CNS), the gastrointestinal (GI) tract, and the respiratory system, makes it a primary candidate for studying systemic homeostasis.
The Signaling Mechanism: VPAC1, VPAC2, and cAMP
The biological activity of VIP is mediated through two primary high-affinity G-protein-coupled receptors (GPCRs): VPAC1 and VPAC2.
- VPAC1: Primarily expressed in the lung, liver, intestine, and T-lymphocytes. It is often associated with the constitutive regulation of immune responses.
- VPAC2: Frequently found in smooth muscle, the pancreas, and the central nervous system (specifically the suprachiasmatic nucleus).
When VIP binds to these receptors, it triggers the activation of adenylate cyclase. This leads to a rapid increase in intracellular levels of cyclic adenosine monophosphate (cAMP). The elevation of cAMP serves as the primary secondary messenger, activating protein kinase A (PKA) and influencing various transcription factors. In immune cells, this pathway is known to inhibit the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12, while simultaneously promoting the expression of anti-inflammatory mediators.
Research Area: Immune Tolerance and Treg Expansion
One of the most compelling aspects of VIP research is its role in establishing and maintaining immune tolerance. In laboratory models of autoimmune disease, VIP has been studied for its ability to reprogram the immune response from a Th1/Th17 (pro-inflammatory) profile to a Th2/Treg (regulatory/anti-inflammatory) profile.
Regulatory T Cell (Treg) Modulation
Regulatory T cells are the "peacekeepers" of the immune system, preventing the body from attacking its own tissues. Research suggests that VIP may promote the expansion and functional activity of CD4+CD25+Foxp3+ Tregs. By increasing the expression of the Foxp3 transcription factor, VIP helps stabilize the regulatory phenotype, making it a subject of interest for researchers studying conditions like rheumatoid arthritis, Type 1 diabetes, and lupus.
Macrophage Polarization
Beyond T cells, VIP significantly influences macrophage polarization. Macrophages typically exist in two states: M1 (pro-inflammatory/classical activation) and M2 (anti-inflammatory/alternative activation). Investigating VIP has shown that it may facilitate the switch from the M1 state to the reparative M2 state. This shift is critical for tissue healing and the resolution of chronic inflammation.
Research Area: Neuroprotection and Microglial Activation
The central nervous system is highly sensitive to inflammation. Microglia, the resident immune cells of the brain, can become "over-activated," leading to the release of neurotoxic factors. This process, known as neuroinflammation, is a hallmark of neurodegenerative research models.
Inhibiting Microglial Firestorms
Studying VIP in neuronal cell cultures has demonstrated its ability to inhibit microglial activation. By suppressing the production of nitric oxide (NO) and reactive oxygen species (ROS), VIP may protect surrounding neurons from oxidative stress.
Preservation of Neuronal Integrity
In models of Parkinson’s disease and Multiple Sclerosis (specifically the EAE model), researchers have explored how VIP helps maintain the integrity of the blood-brain barrier (BBB) and prevents the infiltration of autoreactive T cells into the CNS. This dual action, acting directly on neurons to promote survival and indirectly by calming the local immune environment, positions VIP as a "master regulator" of neuroprotection.
Research Area: Maintaining the Intestinal Barrier
Given its origins in the gut, VIP remains a cornerstone of gastrointestinal research. The intestinal barrier is a complex layer of epithelial cells held together by tight junction proteins. When this barrier is compromised (a state often referred to as "leaky gut" in colloquial terms), systemic inflammation can occur.
Exploring VIP's role in the gut suggests it helps maintain these tight junctions (such as Occludin and Zonula Occludens-1). By regulating the mucosal immune system, VIP ensures that the gut does not overreact to commensal bacteria, thereby preventing the onset of inflammatory bowel conditions in research models.
The Pharmacokinetic Challenge: Half-Life and Delivery
Despite its potent biological activity, VIP presents a significant challenge for researchers: its rapid clearance. In a biological environment, the half-life of VIP is estimated to be approximately one minute. It is quickly degraded by enzymes such as dipeptidyl peptidase IV (DPP4) and neutral endopeptidase (NEP).
Because of this rapid degradation, traditional systemic administration (like intravenous injection) often fails to maintain therapeutic concentrations for a sufficient duration. This has led to innovative research into:
- Intranasal Delivery: Investigated for its potential to bypass the blood-brain barrier and provide direct access to the CNS.
- Analogs and Formulations: The development of more stable VIP analogs that resist enzymatic breakdown.
- Liposomal Encapsulation: Using lipid-based carriers to protect the peptide from degradation.
Targeted Research Applications
VIP is currently being utilized in laboratory settings to investigate a wide array of physiological disruptions:
- Autoimmune Research: Investigating the stabilization of Treg populations in chronic inflammatory models.
- Neurodegenerative Models: Studying the inhibition of neurotoxicity in Alzheimer’s and Parkinson’s simulations.
- Respiratory Research: Due to its bronchodilatory effects, VIP is studied for its influence on pulmonary hypertension and acute lung injury.
- Circadian Rhythm Studies: Researching the role of VIP in the suprachiasmatic nucleus (SCN) for regulating sleep-wake cycles.
Researchers interested in comparing high-purity materials for these studies can view our full range of compounds at our products page. For detailed quality verification, including purity and identity reports, please visit our COA-s section.
Storage and Handling Guidelines
To ensure the stability and integrity of VIP for laboratory use, strict storage protocols must be followed.
- Lyophilized Powder: Should be stored at -20°C for long-term stability. It is recommended to keep the vial sealed and protected from light and moisture.
- Reconstituted Solution: Once reconstituted with bacteriostatic water or sterile saline, the peptide is significantly more fragile. It should be stored at 4°C and used within a short timeframe (typically 7–14 days). Repeated freeze-thaw cycles must be avoided to prevent denaturation of the peptide chain.
Summary Table: VIP Research Profile
| Property | Description |
|---|---|
| Primary Classification | Neuropeptide / Hormone |
| Receptor Targets | VPAC1, VPAC2 |
| Main Intracellular Signal | cAMP Elevation |
| Immune Impact | Upregulates Tregs, Induces M2 Macrophages |
| CNS Impact | Inhibits Microglial Activation, Protects Neurons |
| Metabolic Stability | Low (~1 minute half-life) |
| Research Contexts | Autoimmunity, Neuroinflammation, Gut Health |
Final Research Considerations
While VIP continues to be a primary focus for scientists looking at the nexus of the neuro-immune axis, it is important to remember that all research must be conducted within the appropriate regulatory framework. The complexity of its receptor interactions and the brevity of its half-life make it a sophisticated tool for advanced laboratory investigations.
For further information on research-grade materials and scientific data, researchers are encouraged to explore the biobulkpeptides.com resources.
DISCLAIMER:
FOR RESEARCH USE ONLY. This compound is strictly for laboratory research purposes and is not intended for human or veterinary diagnostic, therapeutic, or any other clinical use. The information provided here is for educational purposes and based on preclinical research.
NOT FOR HUMAN CONSUMPTION.
All products on this site are intended for in-vitro laboratory research only. Handling of these materials should only be performed by qualified professionals in a controlled environment. Please review our Terms of Service for more details.